Cancer survival rates soar nationwide, but L.A. doctors warn cultural and educational barriers leave some behind

The American Cancer Society’s 2026 report finds five-year cancer survival in the U.S. has risen to 70% (from 49% in the mid-1970s), with dramatic gains since the mid-1990s for hard-to-treat cancers (e.g., myeloma 32%→62%, liver 7%→22%, late-stage lung 20%→37%, melanoma 16%→35%, rectal 8%→18%) and an overall >34% drop in mortality since 1991 (an estimated 4.8 million fewer deaths through 2023). The report highlights persistent disparities — American Indian/Alaska Native populations now have the highest cancer death rates and Black and Latina populations face elevated mortality for specific cancers — linking these gaps to income inequity, historical discrimination (eg, redlining) and environmental exposures. It warns that proposed federal cuts to research and health insurance risk reversing progress, underscoring policy and funding implications for healthcare and biotech stakeholders.

Analysis

Market structure: The headline — 70% five-year survival — favors diagnostics, screening providers, CROs and large-cap oncology drugs with durable, chronic-use franchises (e.g., MRK, BMY). Diagnostics (early-detection) can expand volumes and pricing power (+20–30% TAM growth over 3–5 years if screening uptake rises), while small-cap R&D names that depend on grant funding or single assets face compressions. Payors gain leverage over one-time high-cost therapies as more patients shift to long-term, lower-cost maintenance care.

Risk assessment: Key tail risks are federal research/healthcare cuts (>5% NIH or material Medicaid/ACA cuts within 12–18 months) and aggressive drug‑pricing policy (CMS negotiation or reference pricing reducing oncology ASPs by >10%), each able to rerate beneficiaries. Short-term (days–weeks): headlines on budget votes/CMS guidance; medium (3–12 months): trial readouts and screening guideline updates; long-term (3–5 years): structural survivorship demand for chronic-care services. Hidden dependencies include payer coverage decisions for new screening tests and reliance of early-detection businesses on reimbursement codes.

Trade implications: Bullet strategies — overweight diagnostics and CROs, selective long in large-cap oncology, hedge policy risk via index/ETF puts. Use 6–18 month horizons: buy 9–15 month calls on EXAS/HOLX and 12-month exposure to IQV/ICLR; hedge with put spreads on XBI or biotech indices. Position sizing should cap single-name exposure at 2–3% of fund NAV and include stop-loss thresholds (15% on equities, 30% on options premium).

Contrarian angles: Consensus buys big pharma; underappreciated is survivorship-driven demand for home-health, behavioral health and chronic-care devices (potential longs: home-health chains, telehealth). Conversely, diagnostics may be overbought if payors impose strict coverage — a 20%+ move up without provisional reimbursement is a red flag. Historical parallel: PSA screening waves show rapid uptake then payer pushback — monitor coverage milestones tightly.

Key Decisions for Investors

• Establish a 2.5% long position in Exact Sciences (EXAS) with a 6–18 month horizon to capture screening adoption; target +30% upside, set a hard stop at -15%, and scale out if CMS grants a unique CPT/reimbursement code.
• Add a 2% long exposure split between IQVIA (IQV) and ICON (ICLR) to play higher trial volumes and survivorship studies; hold 12–24 months, expect revenue CAGR lift of 6–10%; trim if QoQ bookings growth <3% for two consecutive quarters.
• Initiate a 2% long in Merck (MRK) to capture durable oncology franchise cashflows; use a 12-month horizon, target total return +20%, and reduce to <1% if proposed Medicare price negotiation scenarios imply >10% downside to drug ASPs for MRK labels.
• Purchase a 3‑month put spread on the SPDR S&P Biotech ETF (XBI) (buy 3–6 month ATM puts, sell lower strike for cost reduction) sized to hedge ~5% of healthcare exposure to protect against policy-driven derating; unwind if Congressional budget proposals show NIH cuts <3% or within 60 days of favorable CMS guidance.